Introduction
The Ebola virus continues to pose significant public health challenges, particularly in regions of Central Africa. The recent outbreak in the Democratic Republic of the Congo (DRC), caused by the Bundibugyo ebolavirus species, has been declared a Public Health Emergency of International Concern by the World Health Organization. Pregnant individuals represent a uniquely vulnerable population in Ebola virus disease (EVD), given historically high rates of maternal mortality, vertical transmission, and adverse pregnancy outcomes. Advances in clinical management, vaccines, and therapeutics have improved outcomes in recent years; however, knowledge gaps remain, especially concerning infection with Bundibugyo ebolavirus and its effects on pregnancy. This article provides an evidence-based update for clinicians and researchers regarding EVD in pregnancy, integrating recent findings and highlighting critical research and clinical needs.
Highlight
- Recent outbreaks demonstrate lower maternal mortality in Ebola virus disease than historic data suggest.
- Vertical transmission to fetus and neonatal mortality rates remain alarmingly high.
- Bundibugyo ebolavirus—the agent in the current DRC outbreak—has understudied impacts on pregnancy outcomes.
- The inclusion of pregnant individuals in therapeutic and vaccine trials is crucial to establish safety and efficacy.
Disease Burden and Clinical Context in Pregnancy
Ebola virus disease historically carries poor prognosis for pregnant individuals, with maternal mortality rates frequently reported above 75%. Pregnancies complicated by EVD commonly result in miscarriage, stillbirth, or neonatal death due to viral invasion of the placenta and fetal tissues. Vertical transmission occurs through placental passage or during delivery. Neonates infected in utero often succumb within days of birth. This dual threat to both pregnant individuals and their offspring underscores an urgent unmet medical need to develop safe and effective prevention and treatment strategies.
The Bundibugyo ebolavirus species is less well characterized compared to Zaire ebolavirus, which was the predominant strain in major outbreaks like West Africa (2013-2016). Early clinical evidence suggests possible differences in virulence and outcomes, emphasizing the importance of outbreak-specific data to guide care and public health interventions.
Clinical Advances and Study Design Considerations
Recent breakthroughs in EVD management include the development of Ebola vaccines such as rVSV-ZEBOV and monoclonal antibody therapeutics like REGN-EB3 and mAb114, which demonstrated efficacy in reducing mortality in clinical trials predominantly enrolling non-pregnant adults. However, pregnant individuals were largely excluded from initial trials out of safety concerns. These exclusion criteria limit the generalizability of findings and impede evidence-based guidance for this high-risk population.
Current outbreak responses emphasize the inclusion of pregnant individuals in carefully monitored clinical trials to generate robust safety and efficacy data. Observational cohort studies and registry data are also critical to capture real-world outcomes and adverse events, informing clinical guidelines adaptation for pregnancy.
Key clinical endpoints to evaluate in pregnancy-specific EVD studies include:
– Maternal survival and morbidity
– Pregnancy outcomes (miscarriage, stillbirth, preterm birth)
– Neonatal infection and survival
– Safety profiles of investigational therapeutics and vaccines
Key Findings
Recent surveillance and observational data have provided updated estimates for maternal outcomes. While still grave, maternal mortality rates have been observed at lower levels than previously documented, potentially reflecting improvements in supportive care and early diagnosis. Nonetheless, vertical transmission remains a major concern, with neonatal mortality rates remaining near 100% in affected pregnancies without intervention.
No licensed therapeutics or vaccines are currently authorized specifically for pregnant patients affected by Bundibugyo ebolavirus. Nevertheless, preliminary compassionate use reports and animal model data suggest that promising candidate treatments may be tolerated in pregnancy with potential benefit. These candidates require systematic evaluation in prospective trials.
The continued high rates of adverse fetal outcomes underscore the biological plausibility of viral tropism for placental and fetal tissues, demanding intensified research into mechanisms to disrupt vertical transmission pathways.
Expert Commentary
Leading experts emphasize that failure to include pregnant individuals in research perpetuates a cycle of uncertainty and inequity. The recent DRC outbreak highlights the ethical imperative to balance potential risks with expected benefits through rigorous trial design, adequate informed consent, and robust pharmacovigilance.
Emerging guidelines advocate for integrated maternal-fetal approaches to EVD management, including multidisciplinary teams of infectious disease specialists, obstetricians, neonatologists, and public health officials. This comprehensive model aims to improve survival and long-term outcomes.
Limitations of current knowledge include small sample sizes, outbreak heterogeneity, and challenges in conducting clinical trials during public health emergencies. Methodological innovations such as adaptive trial platforms and real-time data sharing are critical to overcome these barriers.
Conclusion
The evolving landscape of Ebola virus disease in pregnancy demonstrates meaningful progress in maternal survival but persistent challenges with neonatal transmission and death. The specific role and impact of Bundibugyo ebolavirus in pregnant populations remain incompletely understood. Future research must prioritize the ethical inclusion of pregnant individuals in clinical trials of vaccines and therapeutics, standardized outcome reporting, and biological studies of vertical transmission mechanisms.
Health systems should integrate updated evidence-based clinical guidelines with community engagement to optimize care delivery during outbreaks. Addressing these gaps is essential to mitigate the dual threat posed by Ebola virus to mothers and their infants.
Funding and clinical trials
Information on funding sources or clinical trial registration relevant to investigational therapeutics in pregnant populations was not provided in the review article. Ongoing clinical trials registered on clinicaltrials.gov should be consulted for up-to-date enrollment and protocol information.
References
1. Joseph NT, Rasmussen SA, Meaney-Delman D, Jernigan DB, Jamieson DJ. Ebola Virus in Pregnancy. Obstet Gynecol. 2026 Jul 2. PMID: 42390951.
2. Caluwaerts S, et al. Maternal and fetal outcomes in the Ebola virus disease outbreak: a systematic review. PLoS One. 2016.
3. PREVAIL II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016.
4. WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers. 2014.
5. Uyeki TM, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016.
